Phase IIGLP-1
Compound 61615
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061615
Risk Class
LOW
Last Audit
May 7, 2108
Research Abstract
GLP-1 candidate engineered for metabolic regulation initiatives with automated dossier coverage.
Compound 61615 is a glp-1 asset inside glp-1 innovation track initiatives, optimized for metabolic regulation and cardiometabolic recovery.
The dossier currently sits in phase ii with a low risk rating, meaning it is cleared for baseline monitoring protocols.
Supply records cite CAS AUTO-061615 with updates logged 2108-05-07.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Metabolic regulationCardiometabolic recovery
Nomenclature
CX-61615GLP-1 Program 61615
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061615
- [2] Operations Pulse • GLP-1 innovation track
- [3] Risk Governance Ledger • LOW clearance for COMPOUND-61615